FDA clears Medtox's drugs-of-abuse products:
This article was originally published in Clinica
Executive Summary
Medtox Diagnostics, a subsidiary of Medtox Scientific, has received US FDA 510(k) marketing clearance for its Profile-ER device and for 10 configurations of its Verdict-II product line. The Profile-ER is an on-site, drugs-of-abuse test that can screen for nine commonly abused drugs. The product, which is targeted at hospital laboratories for emergency response screening to patients who have taken a drug overdose, involves a one-step procedure and produces a qualitative result in seven minutes. The Verdict-II was developed for the prison, parole and rehabilitation markets and now consists of 13 different configurations to detect between one and five drugs-of-abuse, says the Burlington, North Carolina company.